Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer

Journal of Clinical Oncology

Volumn 29, Issue 35, 2011, Pages 4627-4632

  Wang, Samuel J ^a   Lemieux, Andrew ^a   Kalpathy Cramer, Jayashree ^a   Ord, Celine B ^a   Walker, Gary V ^c   Fuller, C David ^d   Kim, Jong Sung ^b   Thomas Jr , Charles R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND STATE UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGISTRY; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; GALLBLADDER CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

AGED; CHEMORADIOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; NOMOGRAMS; SEER PROGRAM; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 83255162611     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.8020     Document Type: Article

References (55)

1. Bartlett DL, Ramanathan RK, Deutsch M, et al.: Cancer of the biliary tree, in DeVita VT Jr (ed): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 2004
2. Thomas CR, Fuller CD (eds): Biliary Tract and Gallbladder Cancer: Diagnosis and Therapy (ed 1). New York, NY, Demos Medical Publishing, 2008, p 336
3. Yee K, Sheppard BC, Domreis J, et al.: Cancers of the gallbladder and biliary ducts. Oncology (Williston Park) 16:939- 46:949, 2002
4. Reddy SK, Clary BM: Surgical management of gallbladder cancer. Surg Oncol Clin N Am 18:307-324, ix, 2009
5. de Aretxabala X, Roa I, Berrios M, et al.: Chemoradiotherapy in gallbladder cancer. J Surg Oncol 93:699-704, 2006 (Pubitemid 43855701)
6. Houry S, Barrier A, Huguier M: Irradiation therapy for gallbladder carcinoma: Recent advances. J Hepatobiliary Pancreat Surg 8:518-524, 2001 (Pubitemid 33690569)
7. Kresl JJ, Schild SE, Henning GT, et al.: Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 52:167-175, 2002 (Pubitemid 34044114)
8. Czito BG, Hurwitz HI, Clough RW, et al.: Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: A 23-year experience. Int J Radiat Oncol Biol Phys 62:1030-1034, 2005 (Pubitemid 40884414)
9. Baeza MR, Reyes JM, del Castillo C: Postoperative adjuvant radiochemotherapy in the treatment of gallbladder cancer. Presented at the 47th Annual Meeting of the American Society of Therapeutic Radiation Oncology, Denver, CO, October 16-20, 2005
10. Gold DG, Miller RC, Haddock MG, et al.: Adjuvant therapy for gallbladder carcinoma: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 75:150-155, 2009
11. Cho SY, Kim SH, Park SJ, et al.: Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol 102:87-93, 2010
12. SWOG 0809: A phase II trial of adjuvant capecitabine/gemcitabine chemotherapy followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC). http://clinicaltrials.gov/ct2/show/ NCT00789958
13. Wang SJ, Fuller CD, Kim JS, et al.: Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol 26:2112-2117, 2008
14. SEER: SEER*Stat Database: Incidence - SEER 17 Regs Public Use, Nov 2005 Sub (1973-2003 varying), National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission, 2006
15. SEER-Medicare: SEER-Medicare linked database. http://healthservices. cancer.gov/seermedicare
16. Harrell FE: Regression Modeling Strategies. New York, NY, Springer-Verlag, 2001
17. Austin PC: The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making 29:661-677, 2009
18. Kalpathy-Cramer J, Hersh W, Kim JS, et al.: Survival prediction models for estimating the benefit of post-operative radiation therapy for gallbladder cancer and lung cancer. AMIA Annu Symp Proc 348-352, 2008
19. Wang SJ, Kalpathy-Cramer J, Fuller CD, et al.: Parametric survival models for predicting the benefit of adjuvant chemoradiotherapy in gallbladder cancer. AMIA Annu Symp Proc 847-851, 2010
20. Akaike H: A new look at the statistical model identification. IEEE Trans Autom Control 19:716-723, 1974
21. Freedman AN, Seminara D, Gail MH, et al.: Cancer risk prediction models: A workshop on development, evaluation, and application. J Natl Cancer Inst 97:715-723, 2005 (Pubitemid 40872378)
22. Kattan MW, Zelefsky MJ, Kupelian PA, et al.: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352-3359, 2000
23. Kattan MW: Nomograms are superior to staging and risk grouping systems for identifying highrisk patients: Preoperative application in prostate cancer. Curr Opin Urol 13:111-116, 2003
24. Stephenson AJ, Scardino PT, Eastham JA, et al.: Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23:7005-7012, 2005
25. Stephenson AJ, Scardino PT, Eastham JA, et al.: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98:715-717, 2006 (Pubitemid 43821789)
26. Stephenson AJ, Scardino PT, Kattan MW, et al.: Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035-2041, 2007 (Pubitemid 46972788)
27. Ravdin PM: A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients. Bull Cancer 82 5:561s-564s, 1995 (suppl)
28. Ravdin PM: A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 23:43-50, 1996
29. Ravdin PM, Siminoff LA, Davis GJ, et al.: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001 (Pubitemid 32176272)
30. Olivotto IA, Bajdik CD, Ravdin PM, et al.: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005 (Pubitemid 46179461)
31. Rouzier R, Pusztai L, Delaloge S, et al.: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23:8331-8339, 2005
32. Brennan MF, Kattan MW, Klimstra D, et al.: Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 240:293-298, 2004 (Pubitemid 38963021)
33. Kattan MW, Karpeh MS, Mazumdar M, et al.: Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21:3647-3650, 2003 (Pubitemid 46594058)
34. Piehler JM, Crichlow RW: Primary carcinoma of the gallbladder. Surg Gynecol Obstet 147:929-942, 1978 (Pubitemid 9079288)
35. Houry S, Schlienger M, Huguier M, et al.: Gallbladder carcinoma: Role of radiation therapy. Br J Surg 76:448-450, 1989 (Pubitemid 19126599)
36. Arnaud JP, Casa C, Georgeac C, et al.: Primary carcinoma of the gallbladder: Review of 143 cases. Hepatogastroenterology 42:811-815, 1995 (Pubitemid 26026438)
37. Davila JA, Chiao EY, Hasche JC, et al.: Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer. Pancreas 38:e18-e25, 2009
38. Rosenbaum PR, Rubin DB: Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79:516-524, 1984
39. D'Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281, 1998
40. Austin PC, Mamdani MM: A comparison of propensity score methods: A case-study estimating the effectiveness of post-AMI statin use. Stat Med 25:2084-2106, 2006 (Pubitemid 43950281)
41. Austin PC: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083-3107, 2009
42. Boag JW: Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J R Stat Soc B 11:15-44, 1949
43. Rutqvist LE, Wallgren A, Nilsson B: Is breast cancer a curable disease? A study of 14,731 women with breast cancer from the Cancer Registry of Norway. Cancer 53:1793-1800, 1984 (Pubitemid 14127527)
44. Gamel JW, Vogel RL, Valagussa P, et al.: Parametric survival analysis of adjuvant therapy for stage II breast cancer. Cancer 74:2483-2490, 1994 (Pubitemid 24320852)
45. Chapman JA, Lickley HL, Trudeau ME, et al.: Ascertaining prognosis for breast cancer in nodenegative patients with innovative survival analysis. Breast J 12:37-47, 2006 (Pubitemid 43381448)
46. Tai P, Chapman JA, Yu E, et al.: Diseasespecific survival for limited-stage small-cell lung cancer affected by statistical method of assessment. BMC Cancer 7:31, 2007
47. Gamel JW, McLean IW: A stable, multivariate extension of the log-normal survival model. Comput Biomed Res 27:148-155, 1994 (Pubitemid 24178506)
48. Fuller CD, Wang SJ, Choi M, et al.: Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: A population-based analysis. Cancer 115:5175-5183, 2009
49. Wang SJ, Fuller CD, Kim JS, et al.: In reply. J Clin Oncol 26:4524-4526, 2008
50. Foster JM, Hoshi H, Gibbs JF, et al.: Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol 14:833-840, 2007 (Pubitemid 46175334)
51. Yokomizo H, Yamane T, Hirata T, et al.: Surgical treatment of pT2 gallbladder carcinoma: A reevaluation of the therapeutic effect of hepatectomy and extrahepatic bile duct resection based on the longterm outcome. Ann Surg Oncol 14:1366-1373, 2007 (Pubitemid 46536809)
52. Jensen EH, Abraham A, Jarosek S, et al.: Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer. Surgery 146:706-711, 2009; discussion 711-713
53. Kohya N, Kitahara K, Miyazaki K: Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread. World J Gastroenterol 16: 3567-3572, 2010
54. Harada K, Ochiai T, Inoue K, et al.: Optimal surgical treatment for patients with pT2 gallbladder cancer. Hepatogastroenterology 58:14-19, 2011
55. Fuks D, Regimbeau JM, Le Treut YP, et al.: Incidental gallbladder cancer by the AFC-GBC-2009 study group. World J Surg 35:1887-1897, 2011